<DOC>
	<DOCNO>NCT00894023</DOCNO>
	<brief_summary>Background : Percutaneous coronary intervention ( PCI ) highly effective therapy acute ST-elevation myocardial infarction ( STEMI ) . Adjunctive therapy glycoprotein ( GP ) IIb/IIIa inhibitor result increase patency improve outcome STEMI patient , thrombus , undergo PCI . The investigation novel dose delivery strategy therapy may help improve outcome . Study design : Intracoronary Abciximab With Clearway Catheter trial randomize , open-label , multicenter , trial evaluate effect intracoronary ( IC ) bolus dose abciximab deliver use ClearWay™RX catheter versus intravenous bolus ( IV ) abciximab STEMI angiographically visible thrombus ( Thrombus Grade &gt; 2 ) . All patient arm receive intravenous abciximab infusion follow PCI 12 hour per standard practice . A total 150 patient randomize 1:1 treatment culprit artery IC abciximab ( 75 subject ) IV abciximab ( 75 subject ) addition infusion regimen abciximab administer intravenously initiate follow PCI . The primary endpoint choose evaluate hypothesis infarct size assess Cardiac Magnetic Resonance ( CMR ) . Clinical outcome assess subject hospital discharge 30 day follow-up . Sample size : The number patient include study base estimation sample size need identify statistically significant difference primary end-points two group . The investigator estimate 75 patient would require study group power 80 % detect absolute difference infarct size resolution 15 % two-sided alpha value 0.05 . Conclusion : The purpose study demonstrate IC bolus abciximab deliver ClearWay™RX catheter add post-PCI intravenous infusion regimen abciximab result significant additional clot resolution vivo compare IV bolus abciximab add post PCI intravenous infusion regimen abciximab . The primary endpoint choose evaluate hypothesis infarct size assess CMR .</brief_summary>
	<brief_title>Intracoronary Abciximab With Clearway Catheter</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>1 . Patients ( men woman ) least 18 year age 2 . STEMI : Presenting ischemic chest discomfort &gt; 20 minute &lt; 6 hour duration suggestive acute myocardial infarction AND ST elevation &gt; 1 mm ( &gt; 0.1 mV ) two contiguous limb lead OR &gt; 2 mm ( &gt; 0.2 mV ) two contiguous precordial lead 3 . Must sign informed consent form prior performance studyrelated procedure 4 . Native dominant proximal culprit vessel 2.5 mm diameter 5 . Angiographically identifiable thrombus ( presence fill defect within coronary lumen surround contrast medium observe multiple projection , without calcium within fill defect , persistence contrast medium within coronary lumen ) 6 . PrePCI Thrombus score ( TS ) ≥ 2 ( angiographically apparent thrombus &gt; ½ vessel diameter ) 7 . PrePCI TIMI flow grade 02 1 . Previous PCI IRA 2 . Previous myocardial infarction coronary artery bypass graft 3 . Cardiogenic shock 4 . Three vessel disease 5 . Left main disease 6 . Severe valvular heart disease 7 . Rescue PCI ( PCI follow fibrinolytic administration ) 8 . Facilitated PCI ( PCI follow fibrinolytic GP IIb/IIIa inhibition ) 9 . Contraindication GP IIb/IIIa inhibitor excess bleed risk thrombocytopenia 10 . Current participation another investigational trial 11 . Exclusion criterion MRI image include implanted pacemaker , defibrillator , metallic intracranial implant , severe claustrophobia , BMI &gt; 35 kg/m² , atrial fibrillation know well control extrasystole ( bad image ) , allergy gadoliniumDTPA 12 . Enrolment patient estimate glomerular filtration rate &lt; 30 ml/min/1.73 m2 carefully evaluate consider gadolinium chelateassociated risk nephrogenic systemic fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Patients AMI</keyword>
</DOC>